Physician profile
Jane Kapustin
NPI 1114921681
$44,414.14
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,603 · 2022: $12K · 2023: $9,867 · 2024: $7,825 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,189 · Consulting Fee: $3,740 · Travel and Lodging: $561 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,860.75 |
| Food and Beverage | $6,188.69 |
| Consulting Fee | $3,740.00 |
| Travel and Lodging | $561.19 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28,040.20 | 2021-2025 | |
| Cequr Corporation | $5,014.62 | 2022-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $4,751.28 | 2025 | Rezdiffra |
| Novo Nordisk INC | $1,227.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $987.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $873.78 | 2021-2024 | Farxiga |
| Acella Pharmaceuticals, LLC | $735.00 | 2021 | |
| Corcept Therapeutics | $726.44 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $220.45 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Zealand Pharma US, INC. | $181.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.90 | 2022-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $163.12 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $151.55 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $150.95 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.04 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $118.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $114.93 | 2021-2023 | |
| Abbott Laboratories | $110.02 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $95.81 | 2021-2022 | |
| Dexcom, INC. | $87.71 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $57.71 | 2024 | Repatha, Tepezza, Otezla |
| Medtronic, INC. | $52.13 | 2022 | |
| Ascendis Pharma Endocrinology INC | $46.19 | 2023-2025 | Yorvipath |
| Baxter Healthcare | $41.47 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sequel Med Tech, LLC | $38.99 | 2025 | Twiist |
| Lifescan, INC. | $32.35 | 2022 | |
| Antares Pharma, INC. | $23.53 | 2025 | Xyosted |
| Philips North America LLC | $19.08 | 2022 | |
| Globus Medical, INC. | $17.51 | 2025 | Senza |
| Tolmar, INC. | $15.27 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kapustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.